Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsEndless Resistance. Endless Antibiotics?The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.Interaction of Avibactam with Class B Metallo-β-Lactamases.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Role of Residues W228 and Y233 in the Structure and Activity of Metallo-β-Lactamase GIM-1.Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.Intra-abdominal Infections: The Role of Anaerobes, Enterococci, Fungi, and Multidrug-Resistant Organisms.Basis for selecting optimum antibiotic regimens for secondary peritonitis.Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.An update on emerging therapies for urinary tract infections.Drug treatments for prosthetic joint infections in the era of multidrug resistance.Multidrug-resistant bacteria in hematology patients: emerging threats.Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections.The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.Sparing carbapenem usage.Use of Continuous-Infusion Ceftolozane/Tazobactam in a Multidrug-Resistant Pseudomonas aeruginosa Urinary Tract Infection in the Outpatient Setting.High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?Microspectrofluorimetry to dissect the permeation of ceftazidime in Gram-negative bacteria.Antibiotic resistance: challenges and successes in respiratory infection.Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.[Antibiotic transport and membrane permeability: new insights to fight bacterial resistance].in vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam Against Resistant Gram-Negative Bacilli.Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.Tristemma hirtum and Five Other Cameroonian Edible Plants with Weak or No Antibacterial Effects Modulate the Activities of Antibiotics against Gram-Negative Multidrug-Resistant Phenotypes.A Prospective Evaluation of Two Rapid Phenotypical Antimicrobial Susceptibility Technologies for the Diagnostic Stewardship of Sepsis.The Infinity War: How to Cope with Carbapenem-resistantβ-lactam/β-lactamase inhibitor combinations: an update
P2860
Q26739860-E4AF3891-2F9D-412D-A841-4EF063112C2DQ26747429-9446897E-DE34-4FC0-B0FD-091532DF0539Q28822179-C33E5B09-C19B-42F5-AD28-64843F26BF9EQ33892834-D19849F7-BDFA-4C1C-B534-DFCD6BD5CB8DQ34533834-9AECE059-D439-4102-BE4D-B4BC2703E6BDQ36078359-B60D33A7-C703-4563-8D88-9B4342C1E793Q36571912-7F27269C-927F-459D-A860-B544274B2CADQ37119083-90A61131-0A49-45D9-8DB2-DB72CBB1E6F7Q37517993-82E3806B-FA9A-42B2-93F1-1C29ECB5F266Q38633450-00366ABC-1FDA-4206-BC85-75E5823BF7D5Q38740494-877D94F8-09EC-4388-9274-F296767D0B6CQ38751454-9EFBEE42-4EB0-4422-92B2-1E6FC18F99F0Q38800556-FC2724F0-0E22-4007-A053-6757111E97DAQ38838498-F6F75B24-36BF-48FA-A9C7-A76146968175Q38847017-1B7B4AE7-14D7-44A1-B8F3-30A12D81D476Q38875315-92D0B517-2225-4238-8F1A-7F261AD089DCQ39388468-5D83EBE4-2B13-4F8C-99B5-10E182332136Q40274946-78B7D494-2D61-4DE5-B7BD-1CE2D884A2E0Q40282001-C9AC231C-9343-4BB3-BD43-75BF53269D56Q40550507-091A80F4-094A-4FD6-96A9-36D83EB68F05Q41986608-BECAD52E-37F5-489D-9208-E14A8F9F1D91Q44268356-AC8C2F47-A5A0-490E-81E5-2E94A018F43CQ47822967-FF50A26E-971E-47B4-AFC9-D64FF9889A65Q50148090-DD5E89D2-1D02-44AC-9A8B-A10C5F84D6A5Q53682525-E09E80E0-DF05-47AD-863F-92A6F09398EFQ53728436-0D07A3DA-49B7-4EF9-93CE-10F3F9062A2EQ54210700-919959CD-B310-4040-B0EA-E024BEEFA53CQ55004497-65DDE9F2-2B4F-4402-AE24-8C255A26BAA2Q57118424-A443DACF-56C2-4311-9E30-D9B32CD9149EQ57133147-FCE5F53B-B0B3-44AB-8244-08F5CC22CDEE
P2860
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ceftolozane/tazobactam and cef ...... negative bacterial infections.
@en
type
label
Ceftolozane/tazobactam and cef ...... negative bacterial infections.
@en
prefLabel
Ceftolozane/tazobactam and cef ...... negative bacterial infections.
@en
P1476
Ceftolozane/tazobactam and cef ...... negative bacterial infections.
@en
P2093
Elizabeth B Hirsch
Jordan L Liscio
P304
P356
10.1016/J.IJANTIMICAG.2015.05.003
P577
2015-06-14T00:00:00Z